Clinical trials: Brain Stroke
Pharmacodynamics, Pharmacokinetics
Study of BB-025, Alone and After BB-031, in Healthy Volunteers
The goal of this 2-part clinical trial is to learn about the safety and pharmacokinetics (PK) of a single dose of BB-025 when given on its own and after being given BB-031.
- Conditions
- Pharmacodynamics, Pharmacokinetics, Healthy Volunteers
- Trial name
- NCT07202663
- Testing
- BB-025, BB-031
- Where
- Australia
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Basking Biosciences, Inc.
Atrial Fibrillation, Stroke
SIMPLAAFY Clinical Trial
The primary objective is to demonstrate the safety and effectiveness of two monotherapy regimens versus dual antiplatelet (DAPT) therapy following post-implant with the WATCHMAN FLX Pro device in a commercial clinical setting.
- Conditions
- Atrial Fibrillation, Stroke, Bleeding
- Trial name
- SIMPLAAFY (NCT06521463)
- Testing
- WATCHMAN FLX Pro LAAC Device
- Where
- 86 sites in United States
- Volunteers
- 1,857 people
- Sponsor
- Boston Scientific Corporation
Ischemic Stroke
A Study to Monitor Safety and Effectiveness of Approved J&J MedTech Devices in the Treatment of Participants With Ischemic Stroke
The purpose of this study is to collect medical information to monitor the ongoing safety of the J\&J MedTech devices and to understand how well they work when routinely used to treat participants with acute ischemic stroke (a…
- Trial name
- POSEIDON (NCT07760649)
- Volunteers
- 5,000 people
- Sponsor
- Neuravi Limited
Atrial Fibrillation (AF)
Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation
This study is researching an experimental drug called REGN7508 (called "study drug") and how it compares against another treatment called apixaban.
- Trial name
- ROXI-EVEREST (NCT07626411)
- Testing
- REGN7508, Apixaban
- Where
- 54 sites in United States, Canada and 1 more
- Volunteers
- 15,364 people
- Sponsor
- Regeneron Pharmaceuticals
Chronic Ischemic Stroke
CC-101 (f/k/a NR1) Neural Stem Cell Transplantation for Adults With Chronic Ischemic Stroke
The suNR1se II Study is a Phase 2b randomized, controlled, multi-center clinical trial evaluating the efficacy and safety of stereotactic intracerebral administration of CC-101 (f/k/a NR1), an investigational allogeneic neural…
- Trial name
- suNR1se II (NCT07709845)
- Testing
- CC-101 (f/k/a NR1) Intracerebral Transplantation, Tacrolimus
- Volunteers
- 36 people
- Sponsor
- Clarion Cells, Inc.
Stroke, Ischemic
An Investigation Into The Impact Of Enteric Coated Of Aspirin In Patients With Newly Diagnosed Ischemic Stroke.
Uncertainty remains regarding the impact of enteric-coated (EC) aspirin as it relates to the reduction of CV risk. We hypothesize that EC formulation based on the previous report may blunt aspirin response as evidenced by reduced…
- Trial name
- ECASIS (NCT04330872)
- Testing
- Enteric Coated Aspirin Tablet, Plain Aspirin
- Where
- Qatar
- Volunteers
- 42 people
- Sponsor
- Hamad Medical Corporation
Stroke, Acute
A Phase 4 Clinical Study to Investigate the Efficacy and Safety of Naloxone HCI IV in Patients With Stroke
This clinical trial was planned for the purpose to re-evaluate the safety and efficacy of naloxone hydrochloride in ischemic cerebral nerve disorders caused by stroke and cerebral hemorrhage.
- Trial name
- NCT05301712
- Testing
- Naloxone hydrochloride 5.0mg/5ml, Sodium Chloride 45mg/5ml
- Where
- South Korea
- Volunteers
- 446 people
- Sponsor
- Samjin Pharmaceutical Co., Ltd.
Acute Ischemic Stroke
Study of BB-031 in Acute Ischemic Stroke Patients (RAISE)
The purpose of this study is to evaluate the safety and tolerability of ascending doses (Part A) and selected doses (Part B) of BB-031 in acute ischemic stroke patients presenting within 24 hours of stroke onset.
- Trial name
- RAISE (NCT06226805)
- Testing
- BB-031
- Where
- 25 sites in United States, Australia and 1 more
- Volunteers
- 228 people
- Sponsor
- Basking Biosciences, Inc.
Cerebral Infarction
Evaluation of the Safety and Potential Therapeutic Effects of Cordstem-ST in Patients With Cerebral Infarction
The objective of the study is to evaluate the safety and the potential therapeutic effects per dose of Cordstem-ST Intravenous Transplantation in Cerebral Infarction subjects
- Trial name
- NCT02378974
- Testing
- Cordstem-ST
- Where
- South Korea
- Volunteers
- 18 people
- Sponsor
- CHABiotech CO., Ltd
Patent Foramen Ovale
PFx Closure System in Subjects With Cryptogenic Stroke,Transient Ischemic Attack,Migraine or Decompression Illness(PFO)
The primary objective of this study is to demonstrate the safety and performance of the PFx Closure System when utilized for patients with PFOs suffering from cryptogenic stroke, transient ischemic attack, migraine or…
- Trial name
- NCT00335296
- Testing
- PFx catheter
- Where
- 4 sites in Belgium, France and 1 more
- Volunteers
- 100 people
- Sponsor
- Cierra
Stroke, Ischemic
LOTUS: Global Acute Stroke Study Utilizing Penumbra System
The primary objective of this study is to demonstrate safety and effectiveness of the Penumbra System in a population with acute ischemic stroke (AIS) secondary to intracranial large vessel occlusion (LVO).
- Trial name
- LOTUS (NCT04157270)
- Testing
- Penumbra System
- Where
- 2 sites in United States
- Volunteers
- 23 people
- Sponsor
- Penumbra Inc.
Stroke, Hemiplegia
Clinical Study to Evaluate the Implantation of the ActiGait Drop Foot Stimulator System
The objective of this study is to evaluate the efficacy and safety of surgical procedure involving ActiGait - implantable drop foot stimulator.
- Trial name
- NCT01116466
- Testing
- ActiGait
- Volunteers
- 5 people
- Sponsor
- Otto Bock Healthcare Products GmbH
Myocardial Infarction, Cardiovascular Death
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
This study is being carried out to see if a new drug called ticagrelor given twice daily in addition to the ASA therapy decreases the frequency of cardiovascular events (e.g., death from heart disease, heart attack, or stroke).
- Conditions
- Myocardial Infarction, Cardiovascular Death, Atherothrombosis, Stroke
- Trial name
- PEGASUS (NCT01225562)
- Testing
- Ticagrelor 90 mg, Ticagrelor 60 mg
- Where
- 826 sites in United States, Argentina and 29 more
- Volunteers
- 21,379 people
- Sponsor
- AstraZeneca
Acute Ischemic Stroke
Transcranial Ultrasound in Clinical SONothrombolysis
This is a randomized, placebo controlled, parallel group dose escalation trial to evaluate the safety, tolerability, and activity of four sequential dose tiers of MRX-801 and ultrasound as an adjunctive therapy to tissue…
- Trial name
- TUCSON (NCT00504842)
- Testing
- MRX-801
- Where
- 14 sites in United States, France
- Volunteers
- 72 people
- Sponsor
- ImaRx Therapeutics
Chronic Troublesome Sialorrhea, Parkinson's Disease
Clinical Study to Investigate the Efficacy and Safety of Two Dose Levels of NT 201 Versus Placebo in Treating Chronic Troublesome Sialorrhea in Various Neurological Conditions
The objective of this study is to investigate the efficacy and safety of two different dose levels of NT 201 (75 U or 100 U per cycle), compared with placebo, in reducing the salivary flow rate, and the severity and frequency of…
- Conditions
- Chronic Troublesome Sialorrhea, Parkinson's Disease, Post-stroke, Traumatic Brain Injury
- Trial name
- SIAXI (NCT02091739)
- Testing
- IncobotulinumtoxinA (100 Units), IncobotulinumtoxinA (75 Units)
- Where
- 31 sites in Germany, Poland
- Volunteers
- 184 people
- Sponsor
- Merz Pharmaceuticals GmbH
Atrial Fibrillation
Study in Atrial Fibrillation (AF) Patients at High Risk of Stroke
The GARDENIA registry will collect real-world clinical data on the anticoagulant strategies in patients with AF at elevated risk of stroke but also elevated risk of bleeding.
- Trial name
- GARDENIA (NCT05421533)
- Where
- 96 sites in United States, Argentina and 10 more
- Volunteers
- 705 people
- Sponsor
- Anthos Therapeutics, Inc.
Vascular Dementia
Rivastigmine Capsules in Patients With Probable Vascular Dementia
The goal of this research study is to evaluate, in the open-label extension phase, the effectiveness, tolerability and safety of rivastigmine capsules in males and females between the ages of 50 and 85 years old with probable…
- Trial name
- NCT00130338
- Testing
- Rivastigmine
- Volunteers
- 521 people
- Sponsor
- Novartis
Transcatheter Aortic Valve Implantation (TAVI), Aortic Valve Stenosis
Clinical Feasibility and Evaluation Study of POINT-GUARD Embolic Protection Device During TAVR (GUARDIAN)
The purpose of this study is to assess the feasibility and safety of the Transverse Medical, Inc. Point-Guard device. This feasibility study is a limited clinical investigation of the Point-Guard device.
- Conditions
- Transcatheter Aortic Valve Implantation (TAVI), Aortic Valve Stenosis, Transcatheter Aortic Valve Replacement
- Trial name
- GUARDIAN (NCT06962371)
- Testing
- cerebral embolic protection
- Where
- Australia
- Volunteers
- 30 people
- Sponsor
- Transverse Medical, Inc.
Atrial Fibrillation, Stroke
TRENDS: A Prospective Study of the Clinical Significance of Atrial Arrhythmias Detected by Implanted Device Diagnostics
The purpose of this study is to look at the heart rate and rhythm information collected daily in Medtronic implantable pulse generators (IPG), implantable cardioverter defibrillators (ICD) and cardiac resynchronization therapy…
- Conditions
- Atrial Fibrillation, Stroke, Heart Failure
- Trial name
- NCT00279981
- Testing
- Diagnostic
- Where
- 98 sites in United States, Australia and 1 more
- Volunteers
- 3,100 people
- Sponsor
- Medtronic Cardiac Rhythm and Heart Failure
Acute Ischemic Stroke
Safety and Pharmacokinetic Study of Carbamylated Erythropoietin (CEPO) to Treat Patients With Acute Ischemic Stroke
The primary purpose of the study is to determine whether carbamylated erythropoietin (CEPO) dosed once daily for 5 days is a safe treatment for patients who have suffered an acute ischemic stroke.
- Trial name
- NCT00870844
- Testing
- Lu AA24493 (CEPO)
- Where
- 5 sites in Finland, France and 3 more
- Volunteers
- 24 people
- Sponsor
- H. Lundbeck A/S